Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsSUBCUTANEOUSStandard

OXLUMO

LUMASIRAN SODIUM

Standard Dose
EQ 94.5MG BASE/0.5ML (EQ 94.5MG BASE/0.5ML)
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary

Approval overview OXLUMO is listed in Drugs@FDA under application 214103 (NDA).

Review priority: STANDARD Marketing status: Prescription Active ingredient LUMASIRAN SODIUM Form and strength SOLUTION;SUBCUTANEOUS - EQ 94.5MG BASE/0.5ML (EQ 94.5MG BASE/0.5ML) Sponsor ALNYLAM PHARMS INC Submission history Latest submission status date: 2025-04-04 00:00:00.

Structured Monograph

Clinical summary

Approval overview OXLUMO is listed in Drugs@FDA under application 214103 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient LUMASIRAN SODIUM Form and strength SOLUTION;SUBCUTANEOUS - EQ 94.5MG BASE/0.5ML (EQ 94.5MG BASE/0.5ML) Sponsor ALNYLAM PHARMS INC Submission history Latest submission status date: 2025-04-04 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.